MGNX -- MacroGenics | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
MGNX -- MacroGenics

An SI Board Since November 2013

Posts	SubjectMarks	Bans	Symbol
188	21	0	MGNX

Emcee: scaram(o)uche	Type: Moderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
63	Not very much, but every bit of info is step forward. Normally, point is can thi	Miljenko Zuanic	-	9/19/2017
62	PD1/LAG3: >>Tumor LAG-3 expression is associated with response to combina	tuck	-	9/19/2017
61	< MGD013 has a prolonged serum half-life and is being developed for the poten	Miljenko Zuanic	-	9/5/2017
60	MGD013: finance.yahoo.com	Miljenko Zuanic	-	9/5/2017
59	Thanks for your thoughts. Have a great long weekend! Cheers, Tuck	tuck	-	9/2/2017
58	Well, target (CD3xCD123) may be OK, but 4 days cont. infusion/3 days off dosing	Miljenko Zuanic	-	9/1/2017
57	MGD006 may just follow CD3xCD19 path. :-( But I don't see anyone with much o	tuck	-	9/1/2017
56	Hi Tuck, I guess there us room for some CD3xYYY bispecific, but am not sure tha	Miljenko Zuanic	-	9/1/2017
55	MGNX was not putting up any of the development costs after IND, so all they lose	tuck	1	9/1/2017
54	Another one bite the dust, CD3xCD19, finance.yahoo.com Bispecific (including CD	Miljenko Zuanic	-	8/31/2017
53	Another PD-1 deal (from china), IF they (MGNX) want to be "competitive on t	Miljenko Zuanic	-	8/18/2017
52	Bullish crossover in MACD and Stochastic oscillators. breakout watch over 18.58.	hollyhunter	-	8/5/2017
51	>> bought back my August 17.5 puts for a modest profit << Cool.	scaram(o)uche	-	8/4/2017
50	FWIW, on the pop of the last couple of days into this morning, I bought back my	tuck	-	8/4/2017
49	Thanks for the chatter guys. I have nothing to add, except that the pipeline is	scaram(o)uche	-	8/3/2017
48	The point is to do this ahead of P1 results (early), from competitive landscape	tuck	-	8/3/2017
47	<I think it is worth waiting for the next year of data to come in before rati	Miljenko Zuanic	-	8/3/2017
46	The lowest dose with full potential for antitumor activity was 2 mg/kg Q3W Yes,	tuck	-	8/3/2017
45	Keytruda: <Mechanism-based translational models with a focus on intratumor ex	Miljenko Zuanic	-	8/3/2017
44	EARLY, I WAS HOPING THAT PIPELINE WILL BRING FRUIT. Today, they should terminat	Miljenko Zuanic	1	8/3/2017
43	MGA1012 (and other DART): This is 3X to 5X Opd/Key dose/regime! What the facxx	tuck	-	8/3/2017
42	They are spending $~45M on R&D + G&A, so by now they should show some &q	Miljenko Zuanic	-	8/2/2017
41	I think that is is about time to move pass DART hype & nonsense, and do some	Miljenko Zuanic	-	8/2/2017
40	My mistake, there was data on 010 presented some weeks ago at EULAR, and it was	tuck	-	8/2/2017
39	fwiw, I am very tempted at these levels. I have had two nice trips from 15 to 2	mopgcw	-	8/2/2017

Go to reply# or date (mm/dd/yy):